Pages that link to "Q33337445"
Jump to navigation
Jump to search
The following pages link to CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future (Q33337445):
Displaying 50 items.
- DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets (Q21245727) (← links)
- Complexity of type 2 diabetes mellitus data sets emerging from nutrigenomic research: a case for dimensionality reduction? (Q24289423) (← links)
- RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer (Q24298388) (← links)
- Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia (Q24539231) (← links)
- Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas (Q24603535) (← links)
- Molecular mechanisms of chemopreventive phytochemicals against gastroenterological cancer development (Q24616554) (← links)
- Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer (Q24652213) (← links)
- A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines (Q24792846) (← links)
- 5-halogenated pyrimidine lesions within a CpG sequence context mimic 5-methylcytosine by enhancing the binding of the methyl-CpG-binding domain of methyl-CpG-binding protein 2 (MeCP2). (Q24794741) (← links)
- A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation (Q24801375) (← links)
- Gene expression profiling of epithelial ovarian tumours correlated with malignant potential (Q24805553) (← links)
- The DNMT3B C-->T promoter polymorphism and risk of breast cancer in a British population: a case-control study (Q24806265) (← links)
- Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region (Q24810666) (← links)
- Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines (Q25255934) (← links)
- Epigenetics and inheritance of phenotype variation in livestock (Q26742131) (← links)
- Emerging role of cystic fibrosis transmembrane conductance regulator - an epithelial chloride channel in gastrointestinal cancers (Q26753851) (← links)
- Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications (Q26801380) (← links)
- A perspective on dietary phytochemicals and cancer chemoprevention: oxidative stress, nrf2, and epigenomics (Q26852571) (← links)
- Epigenetic Impact on EBV Associated B-Cell Lymphomagenesis (Q28068361) (← links)
- The quest for an effective and safe personalized cell therapy using epigenetic tools (Q28079389) (← links)
- A human tRNA methyltransferase 9-like protein prevents tumour growth by regulating LIN9 and HIF1-α (Q28115094) (← links)
- The power and the promise of DNA methylation markers (Q28188233) (← links)
- Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors (Q28190640) (← links)
- Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer (Q28239595) (← links)
- A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma (Q28247365) (← links)
- MeCP2: the chromatin connection and beyond (Q28256925) (← links)
- Increased microsatellite instability and epigenetic inactivation of the hMLH1 gene in head and neck squamous cell carcinoma (Q28259846) (← links)
- AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity (Q28272449) (← links)
- Head and neck squamous cell carcinoma: mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene (Q28306163) (← links)
- Frequent DNA hypomethylation of human juxtacentromeric BAGE loci in cancer (Q28306838) (← links)
- Clinical implications of interferon-γ genetic and epigenetic variants (Q28383437) (← links)
- The complexity of the Nrf2 pathway: beyond the antioxidant response (Q28389296) (← links)
- High-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistance (Q28474284) (← links)
- Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer (Q28477572) (← links)
- Analysis of distribution of DNA methylation in kidney-renal-clear-cell-carcinoma specific genes using entropy (Q28821026) (← links)
- Changes in DNA Methylation in Mouse Lungs after a Single Intra-Tracheal Administration of Nanomaterials (Q29248387) (← links)
- Epigenetic modifications and human disease (Q29619753) (← links)
- Kaposi's sarcoma-associated herpesvirus genome programming during the early stages of primary infection of peripheral blood mononuclear cells. (Q30369871) (← links)
- Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors (Q30885681) (← links)
- Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data (Q31056438) (← links)
- Association of diminished expression of RASSF1A with promoter methylation in primary gastric cancer from patients of central China (Q33289807) (← links)
- Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: critical evaluation and improvements (Q33298863) (← links)
- Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells (Q33308310) (← links)
- DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection (Q33360111) (← links)
- Promoter DNA hypermethylation and gene repression in undifferentiated Arabidopsis cells (Q33373064) (← links)
- PcG proteins, DNA methylation, and gene repression by chromatin looping. (Q33389249) (← links)
- Phase 2 study of dose-intense temozolomide in recurrent glioblastoma (Q33406808) (← links)
- QSEA-modelling of genome-wide DNA methylation from sequencing enrichment experiments (Q33558221) (← links)
- Genome-wide and gene-specific epigenomic platforms for hepatocellular carcinoma biomarker development trials (Q33562782) (← links)
- Mutation patterns in cancer genomes (Q33564395) (← links)